TY - JOUR
T1 - Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency
AU - Wilson, K. F.
AU - Fielder, P. J.
AU - Guevara-Aguirre, J.
AU - Cohen, P.
AU - Vasconez, O.
AU - Martinez, V.
AU - Martinez, A.
AU - Rosenbloom, A. L.
AU - Rosenfeld, R. G.
PY - 1995
Y1 - 1995
N2 - Objective. The aim of this investigation was to study the effect of relatively high dose IGF-I therapy given for several months, on serum levels of IGF-I, IGF-II and IGFBP-3, and on IGF-I pharmacokinetics in patients with growth hormone insensitivity due to GH receptor dysfunction. Design and patients. Two adolescent subjects from Ecuador were treated with recombinant IGF-I at a dosage of 120 μg/kg s.c. twice daily, in combination with a GnRH analogue for 8 months. Measurements. Serum was sampled at baseline and at 3-8 months, for determination of IGF-I, IGF-II and IGFBP-3 by radioimmunoassay, and for evaluation of IGFBPs and IGFBP-3 protease activity by Western ligand blot and protease assay, respectively. Results. Peak serum IGF-I levels ranged from 272 to 492 μg/l. Mean serum IGF-II levels were decreased concurrently with the increase in IGF-I. Serum IGFBP-3 levels failed to rise with prolonged IGF-I treatment. There was no apparent change in the half-life of IGF-I during the treatment period. Conclusions. IGF administration does not increase serum levels of IGFBP-3 or significantly alter IGF-I pharmacokinetics.
AB - Objective. The aim of this investigation was to study the effect of relatively high dose IGF-I therapy given for several months, on serum levels of IGF-I, IGF-II and IGFBP-3, and on IGF-I pharmacokinetics in patients with growth hormone insensitivity due to GH receptor dysfunction. Design and patients. Two adolescent subjects from Ecuador were treated with recombinant IGF-I at a dosage of 120 μg/kg s.c. twice daily, in combination with a GnRH analogue for 8 months. Measurements. Serum was sampled at baseline and at 3-8 months, for determination of IGF-I, IGF-II and IGFBP-3 by radioimmunoassay, and for evaluation of IGFBPs and IGFBP-3 protease activity by Western ligand blot and protease assay, respectively. Results. Peak serum IGF-I levels ranged from 272 to 492 μg/l. Mean serum IGF-II levels were decreased concurrently with the increase in IGF-I. Serum IGFBP-3 levels failed to rise with prolonged IGF-I treatment. There was no apparent change in the half-life of IGF-I during the treatment period. Conclusions. IGF administration does not increase serum levels of IGFBP-3 or significantly alter IGF-I pharmacokinetics.
UR - http://www.scopus.com/inward/record.url?scp=0028905752&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.1995.tb02649.x
DO - 10.1111/j.1365-2265.1995.tb02649.x
M3 - Artículo
C2 - 7538453
AN - SCOPUS:0028905752
SN - 0300-0664
VL - 42
SP - 399
EP - 407
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 4
ER -
